In a report issued on June 8, David Evans from Kepler Capital downgraded Guerbet SA (GUERF) to Hold, with a price target of EUR35.00.
According to TipRanks.com, Evans is a 4-star analyst with an average return of 8.7% and a 67.3% success rate. Evans covers the Healthcare sector, focusing on stocks such as Quantum Genomics, Innate Pharma, and Crossject SA.
The word on The Street in general, suggests a Hold analyst consensus rating for Guerbet SA with a $42.61 average price target.
See today’s analyst top recommended stocks >>
Guerbet SA’s market cap is currently $734.9M and has a P/E ratio of 24.20. The company has a Price to Book ratio of 2.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Guerbet is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol. It derives the majority of its revenue from the sale of magnetic resonance imaging.
